In Vitro: Sp-5,6-DCl-cBIMPS (0.005, 0.05, 0.5 mM; 60 min) stimulates insulin release from isolated pancreatic islets in a dose and time-dependent manner. Sp-5,6-DCl-cBIMPS (0.005, 0.05, 0.5 mM; 60 min) increases glucose (8.5 mM)-stimulated insulin release. Sp-5,6-DCl-cBIMPS (100 µM; 20 min) inhibits U46619-induced Rho activation in wild-type mouse platelets, and inhibits U46619-induced activation of both Gq and G12/G13 in human platelets.